For the quarter ending 2025-09-30, COCP had $2,963K increase in cash & cash equivalents over the period. -$1,374K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,049 | -4,356 |
| Depreciation and amortization expense | 13 | 46 |
| Right of use assets | 226 | - |
| Stock-based compensation | 48 | 166 |
| Operating lease liabilities | -75 | -148 |
| Prepaid expenses and other current assets | 244 | -148 |
| Tax credit receivable | -1,129 | 427 |
| Deposits | - | 59 |
| Decrease in right of use assets | - | 149 |
| Accounts payable and accrued expenses | -320 | -613 |
| Net cash used in operating activities | -1,362 | -5,094 |
| Purchases of property and equipment | 12 | 0 |
| Net cash used in investing activities | -12 | 0 |
| Proceeds from atm sale of common stock, net of transaction costs | 154 | - |
| Proceeds from registered direct sale of common stock, net of transaction cost | 4,183 | - |
| Net cash provided by financing activities | 4,337 | - |
| Net decrease in cash and restricted cash | 2,963 | -5,094 |
| Cash and cash equivalents at beginning of period | 9,935 | - |
| Cash and cash equivalents at end of period | 7,804 | - |
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)